SCHEMBL5715230

SCHEMBL5715230

Cc1ccc(Cc2ccc(OC(=O)N3CCN(CCCc4cccnc4)CC3)cc2)nc1

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
SIGMAR1 Q99720 3/20 0.45
ADORA3 P0DMS8 1/20 0.45
HTR2A P28223 1/20 0.45
HTR7 P34969 1/20 0.45
OPRM1 P35372 1/20 0.45
ALOX15 P16050 1/20 0.45
HRH2 P25021 2/20 0.43
HRH1 P35367 2/20 0.43
LTA4H P09960 1/20 0.42
FAAH O00519 5/20 0.41
MGLL Q99685 2/20 0.41
PTAFR P25105 1/20 0.40
DRD2 P14416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714317 0.95 KDM4E (0.47) KDM4EALDH1A1HRH2HRH1LTA4H
SCHEMBL5715419 0.93 KDM4E (0.47) KDM4EALDH1A1SIGMAR1ADORA3HTR2A
SCHEMBL5714738 0.89 KDM4E (0.58) KDM4EALDH1A1
SCHEMBL5714958 0.89 SIGMAR1 (0.44) SIGMAR1ADORA3HTR2AHTR7OPRM1
SCHEMBL5715177 0.89 SIGMAR1 (0.44) KDM4EALDH1A1SIGMAR1ADORA3HTR2A
SCHEMBL5714468 0.88 KDM4E (0.49) KDM4EALDH1A1SIGMAR1ADORA3HTR2A
SCHEMBL5714888 0.88 KDM4E (0.47) KDM4EALDH1A1SIGMAR1ADORA3HTR2A
SCHEMBL5714459 0.87 LIPE (0.45) KDM4EALDH1A1SIGMAR1ADORA3HTR2A
SCHEMBL5714814 0.87 TP53 (0.47) KDM4EALDH1A1SIGMAR1ADORA3HTR2A
SCHEMBL5714875 0.87 TP53 (0.47) KDM4EALDH1A1SIGMAR1ADORA3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2006527212-A 2006-11-30 JP claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160820-A1 Substituted piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636187-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111004-A1 SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160820-A1 Substituted piperazine carbamates LIPE, PNLIP, LPL KDM4E 1090/4885ALDH1A1 1504/4885SIGMAR1 2726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.